Cellmid 2017 Annual Report 41
Revenue from continuing operations
Loss before income tax includes the following specific expenses:
Accounting Policy
The income tax expense or benefit for the period is the tax payable on the current period’s taxable income based on the
national income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to
temporary differences, unused tax losses and adjustments recognised for prior periods where applicable.
Deferred tax assets relating to temporary differences and unused tax losses are recognised only to the extent that it is probable
that future taxable profit will be available against which the benefits of the deferred tax asset can be utilised.
Current tax assets and liabilities are offset only where a legally enforceable right of set off exists and it is intended that net
settlement or simultaneous realisation and settlement of the respective asset and liability will occur.
2017 2016
$ $
Consumer health and sale of products 4,496,338 3,120,367
Other revenue:
interest received 56,956 39,509
licence fees and royalties 147,520 205,390
other revenue 21,792 23,636
226,268 268,535
Total Revenue 4,722,606 3,388,902
Other income:
- Government grants 831,408 1,121,562
- Gain on foreign exchange - 95,972
- Other income 6,107 4,672
Total other income 837,515 1,222,206
2017 2016
$ $
Manufacturing sales expense (2,118,717) (1,219,849)
Finance costs (291,173) (195,914)
Defined contribution superannuation expense (188,938) (178,740)
Loss on foreign exchange (61,636) -
Rental expense on leased premises (223,350) (200,133)
Depreciation and amortisation expense (156,386) (161,613)
Research and development expense (599,605) (354,881)